ONCY Oncolytics Biotech, Inc.

7,031

$1.40

$0.00

(0.00%)

Today

Market Cap	$102.76M
Volume (M)	273,853.00
52-Wk High	$3.39
52-Wk Low	$1.09

ST Data

Watchers

New Watcher Rank

Fundamentals

Oncolytics Biotech and SOLTI Present Positive Translational Data at SABCSPR Newswire • 2 days ago

Oncolytics Biotech and SOLTI Present Positive Translational Data at SABCS Oncolytics Biotech and SOLTI Present Positive Translational Data at SABCS PR Newswire SAN DIEGO and CALGARY, AB, Dec. 7, 2023...

Share to Feed

Oncolytics Biotech and SOLTI Present Positive Translational Data at SABCSCNW Group - News Releases • 2 days ago

Oncolytics Biotech and SOLTI Present Positive Translational Data at SABCS Oncolytics Biotech and SOLTI Present Positive Translational Data at SABCS Canada NewsWire SAN DIEGO and CALGARY, AB, Dec. 7...

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer TreatmentPR Newswire • 10 days ago

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment PR Newswire VANCOUVER, BC, Nov. 29, 2023 FN...

Critical Survey: Oncolytics Biotech (NASDAQ:ONCY) & GB Sciences (OTCMKTS:GBLX)Zolmax • 11 days ago

Oncolytics Biotech (NASDAQ:ONCY Get Free Report) and GB Sciences (OTCMKTS:GBLX Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two...

Oncolytics Biotech (NASDAQ:ONCY) Price Target Lowered to $5.00 at HC WainwrightZolmax • 24 days ago

Oncolytics Biotech (NASDAQ:ONCY Get Free Report) had its target price lowered by equities researchers at HC Wainwright from $15.00 to $5.00 in a report released on Monday, Benzinga reports...

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for EfficacyPR Newswire • 30 days ago

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy Oncolytics Announces the Anal Cancer Cohort of the...

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for EfficacyCNW Group - News Releases • 30 days ago

Oncolytics Provides Update on Pancreatic Cancer Program for PelareorepPR Newswire • 30 days ago

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep PR Newswire SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023...

Oncolytics Provides Update on Pancreatic Cancer Program for PelareorepCNW Group - News Releases • 30 days ago

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep Canada NewsWire SAN DIEGO, CA and CALGARY, AB, Nov. 9...

Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments AdvancePR Newswire • about 1 month ago

Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance PR Newswire...